411 related articles for article (PubMed ID: 25012937)
1. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells.
Ganai SA; Kalladi SM; Mahadevan V
J Biomol Struct Dyn; 2015; 33(6):1185-97. PubMed ID: 25012937
[TBL] [Abstract][Full Text] [Related]
2. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA.
Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A
Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782
[TBL] [Abstract][Full Text] [Related]
4. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
5. Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.
Seok YM; Lee HA; Park KM; Hwangbo MH; Kim IK
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):799-808. PubMed ID: 27106211
[TBL] [Abstract][Full Text] [Related]
6. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic landscape of amphetamine and methamphetamine addiction in rodents.
Godino A; Jayanthi S; Cadet JL
Epigenetics; 2015; 10(7):574-80. PubMed ID: 26023847
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity.
Fu Y; Zhang P; Ge J; Cheng J; Dong W; Yuan H; Du Y; Yang M; Sun R; Jiang H
Int J Biochem Cell Biol; 2014 Sep; 54():68-77. PubMed ID: 25019367
[TBL] [Abstract][Full Text] [Related]
9. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes.
Milutinovic S; D'Alessio AC; Detich N; Szyf M
Carcinogenesis; 2007 Mar; 28(3):560-71. PubMed ID: 17012225
[TBL] [Abstract][Full Text] [Related]
10. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
Biochem Pharmacol; 2015 Jun; 95(3):133-44. PubMed ID: 25888926
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
12. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
Ganai SA; Shanmugam K; Mahadevan V
J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations.
Bermúdez-Lugo JA; Perez-Gonzalez O; Rosales-Hernández MC; Ilizaliturri-Flores I; Trujillo-Ferrara J; Correa-Basurto J
J Mol Model; 2012 Jun; 18(6):2301-10. PubMed ID: 21968575
[TBL] [Abstract][Full Text] [Related]
14. Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach.
Sixto-López Y; Bello M; Correa-Basurto J
J Comput Aided Mol Des; 2020 Aug; 34(8):857-878. PubMed ID: 32180123
[TBL] [Abstract][Full Text] [Related]
15. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
[TBL] [Abstract][Full Text] [Related]
16. Identification of an epigenetic signature of early mouse liver regeneration that is disrupted by Zn-HDAC inhibition.
Huang J; Schriefer AE; Yang W; Cliften PF; Rudnick DA
Epigenetics; 2014 Nov; 9(11):1521-31. PubMed ID: 25482284
[TBL] [Abstract][Full Text] [Related]
17. Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3β.
Correa F; Mallard C; Nilsson M; Sandberg M
Neurobiol Dis; 2011 Oct; 44(1):142-51. PubMed ID: 21757005
[TBL] [Abstract][Full Text] [Related]
18. The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities.
Kao CY; Hsu YC; Liu JW; Lee DC; Chung YF; Chiu IM
J Neurochem; 2013 Jul; 126(1):4-18. PubMed ID: 23647222
[TBL] [Abstract][Full Text] [Related]
19. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat.
Khan S; Jena G; Tikoo K
Exp Mol Pathol; 2015 Apr; 98(2):230-9. PubMed ID: 25576297
[TBL] [Abstract][Full Text] [Related]
20. The activity of antiepileptic drugs as histone deacetylase inhibitors.
Eyal S; Yagen B; Sobol E; Altschuler Y; Shmuel M; Bialer M
Epilepsia; 2004 Jul; 45(7):737-44. PubMed ID: 15230695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
